The UK has become the first country in Europe to approve a new once-a-day pill to aid weight loss and treat type 2 diabetes.
Orforglipron, known as Foundayo and made by pharmaceutical giant Eli Lilly, was authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday.
Orforglipron is a GLP-1 receptor agonist, a type of medication which helps lower blood sugar levels, slows the digestion of food and can reduce appetite.
Alongside a reduced-calorie diet and increased physical activity, orforglipron is licensed for people with a body mass index (BMI) of 30 or above, or those with a BMI of between 27 and 30 and at least one weight-related condition.
It can also be used to improve blood sugars in patients with poorly controlled type 2 diabetes.
The pill is taken once a day, at any time, with no food or water restrictions.
The most common side effects for those taking orforglipron are nausea, constipation, diarrhoea, vomiting, dyspepsia (indigestion), and abdominal pain.
Source: The Independent, 10 August 2026
Recommended Comments
Create an account or sign in to comment